Deep Intelligent Pharma Raises Nearly US$50 Million in Series D Funding to Reinvent the Full Clinical Trial Workflow with AI
Want to read in a language you're more familiar with?
Deep Intelligent Pharma (DIP) secures nearly US$50 million in Series D funding to accelerate its AI-driven transformation of the entire clinical trial lifecycle.
On December 11, 2025, Deep Intelligent Pharma (DIP), a global leader in AI-driven drug development, announced that it has raised nearly US$50 million in Series D financing. The round was led by CDH Baifu, with continued participation from existing investors New Ding Capital and Sequoia China. Index Capital served as the exclusive financial advisor. The new funds will be used to further develop DIP’s “multi-agent collaborative network” and expand its global delivery infrastructure.
Founded in 2017, DIP has, over the past three years, evolved from validating isolated AI technologies to building an AI-native clinical research platform, positioning itself as a full-process clinical trial solution provider. Its core technology, the mult i-agent collaboration system, is built on a “cognitive atom theory” that breaks clinical studies into tens of thousands of atomic tasks, each completed by specialized AI agents. These agents interact through synapse-like network connections, enabling a level of domain expertise that surpasses general-purpose large models.
On the business front, DIP is moving beyond the industry’s typical hourly billing model toward a milestone-based value pricing approach. In terms of data protection, the company adheres to strict principles of “data stays on-site” and “models do not retain memory.” All projects run inside independent physical sandboxes, which are destroyed upon project completion.
To date, DIP has served over 1,000 pharmaceutical companies, delivering more than 40,000 projects, including supporting Japan’s Immunorock in obtaining one-time PMDA approval. Founder Li Xing says the company aims to build a “pharmaceutical R&D operating system” that frees scientists to focus on true innovation.
